Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults

Summary

This Phase 1 study will evaluate the safety, tolerability, and immune responses of investigational CH505 HIV vaccine regimens in adults in overall good health without HIV. Participants will receive CH505 protein nanoparticle vaccines (DV901-NP) formulated with the investigational adjuvant ACU-026-001-1, followed by either CH505 protein nanoparticle (DV902-NP) or CH505 mRNA vaccine boosters. The study will assess the ability of these regimens to induce HIV-specific immune responses, including B-cell responses associated with the development of broadly neutralizing antibodies.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• HIV

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 55 years

Sex

All

Healthy volunteers

Accepted

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Last updated on ClinicalTrials.gov

October 9, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites